Bengaluru: Biocon Biologics on Monday said it has inked an out-licensing agreement with Yoshindo Inc to commercialise its two biosimilar assets in the Japenese market.
Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.